NCT03902613View on ClinicalTrials.gov

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 7, 2019

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions
Bipolar Depression
Interventions
DRUG

Lurasidone

Participant will have an open label trial of lurasidone for eight weeks.

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
collaborator

Columbia University

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT03902613 - 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder | Biotech Hunter | Biotech Hunter